Regeneron: Study shows use of 2-antibody combo drug can help prevent serious illness, death

The findings showed the cocktail called Remdesivir reduced hospitalization or death by 70%. It also reduced the average hospital stay from 14 days to 10 days.

News 12 Staff

Mar 24, 2021, 2:21 AM

Updated 1,156 days ago

Share:

Tarrytown-based Regeneron Pharmaceuticals released the results of its phase three trial of Remdesivir on Tuesday.
The findings showed the cocktail called Remdesivir reduced hospitalization or death by 70%. It also reduced the average hospital stay from 14 days to 10 days.
This is significant because this isn't a vaccine. It doesn't prevent the disease, it's for treating people after they're infected.
SEARCH FOR A CURE: Statistics and State Resources
Former President Donald Trump took the cocktail, which was still unproven, when he had COVID-19 in October.
Trump said Remdesivir did wonders for him.
The treatment is just as effective at half the dose, Regeneron also said.


More from News 12